Drug intelligence / Profile preview

NV-102

Development stage: Preclinical
Lead developer: nVector
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies

Overview

NV-102 (also referred to as nAV-102) is an adeno-associated virus (AAV) gene therapy vector developed by nVector for the treatment of Huntington's Disease and Parkinson's Disease. Built on the company's proprietary GreenGlia Technology platform, NV-102 is designed to modulate neuroinflammation by targeting endogenous chitinases and chitinase-like proteins. This mechanism aims to alter shared neuroinflammatory processes that contribute to the progression of neurodegenerative conditions, thereby providing neuroprotective and anti-inflammatory benefits. NV-102 is intended to be used as a standalone therapy or potentially paired with other therapeutic vectors to enhance treatment outcomes in central nervous system (CNS) diseases.

Targets

CHI3L1 (Chitinase-3-like protein 1)

Beyond the preview

Go deeper on NV-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV-102.

Explore the full profile